Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4501 Target Snapshot

Ribosomal protein S6 kinase beta-1 · SINGLE PROTEIN · Homo sapiens

3,802Compounds
513Assays
8Approved Drugs
3,123.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Ribosomal protein S6 kinase beta-1 shows clinical signal disease relevance led by cancer. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P23443. Start with cancer, then reuse UniProt P23443 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt P23443 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
cancer

Ribosomal protein S6 kinase beta-1 shows clinical signal disease relevance led by cancer. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with cancer because it currently carries clinical signal support. Linked drugs include LY-2584702. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Ribosomal protein S6 kinase beta-1 as ChEMBL target CHEMBL4501, mapped to UniProt P23443. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Ribosomal protein S6 kinase beta-1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4501
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P23443
Ribosomal protein S6 kinase beta-1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Ribosomal protein S6 kinase beta-1 is the right protein anchor across sources, using UniProt P23443 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRibosomal protein S6 kinase beta-1
UniProt AccessionP23443
Component TypeProtein
Sequence Length525 aa

Ribosomal protein S6 kinase beta-1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Ribosomal protein S6 kinase beta-1, mapped to UniProt P23443. Sequence length is 525 aa.

Mapped IDP23443
Review nameRibosomal protein S6 kinase beta-1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Ribosomal protein S6 kinase beta-1 shows clinical signal disease relevance led by cancer. 4 more disease programs remain visible in the same review block.

Clinical signal Phase I
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugLY-2584702
Clinical signal Phase I
metastasis
1 linked drug · 1 direct · 1 efficacy
Linked drugLY-2584702
Clinical signal Phase I
neuroendocrine neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugLY-2584702
Clinical signal Phase I
non-small cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugLY-2584702
Clinical signal Phase I
renal cell carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugLY-2584702
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with cancer because it currently carries clinical signal support. Linked drugs include LY-2584702. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

8
Approved
10
Phase III
13
Phase II
11
Phase I
Assay Mix

Activity Type Distribution

IC502,080.0
KI731.0
KD312.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3936990 10.22 IC50 0.06 Preclinical
CHEMBL3899716 10.0 IC50 0.1 Preclinical
CHEMBL3966806 9.96 IC50 0.11 Preclinical
CHEMBL3675393 9.92 IC50 0.12 Preclinical
CHEMBL3675394 9.85 IC50 0.14 Preclinical
CHEMBL3685328 9.7 IC50 0.2 Preclinical
CHEMBL3906990 9.7 IC50 0.2 Preclinical
CHEMBL3980521 9.7 IC50 0.2 Preclinical
CHEMBL3981085 9.59 IC50 0.26 Preclinical
CHEMBL3675395 9.55 IC50 0.28 Preclinical
Distribution

pChEMBL Value Distribution

130
5.0
185
5.5
311
6.0
294
6.5
337
7.0
311
7.5
305
8.0
214
8.5
84
9.0
8
9.5
pChEMBL
Approved Drugs

Approved Drugs

NINTEDANIB
CHEMBL502835
Approved 2014
BOSUTINIB
CHEMBL288441
Approved 2012
CRIZOTINIB
CHEMBL601719
Approved 2011
SUNITINIB
CHEMBL535
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
Assay Landscape

Assay Landscape

513
Total Assays
1,624
Tested Compounds
2
Assay Types
Binding — 511 assays, 1,624 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 395 1,495 7.3
cell-based format 51 61 7.5
assay format 44 31 7.7
subcellular format 20 5 6.6
organism-based format 1 32 7.3
Functional — 2 assays, 354 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 354 6.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine